

The Canadian Association for the Study of the Liver (CASL) and the Canadian Liver Foundation (CLF) acknowledge the following organizations for their support of our collective mission to improve the liver health of all Canadians through research, education, patient support and advocacy.



SPECIALTY Rx
SOLUTIONS

abbvie



In keeping with the Canadian Medical Association Guidelines, program content and selection of speakers are the sole responsibility of the Scientific Committee. Funders have had no input into the content, speakers or activities of the meeting.



Welcome Message

On behalf of everyone at the Canadian Association for the Study of the Liver, the Canadian Liver Foundation and the organizing committee, we are very pleased to welcome you to the 2019 Canadian Association for the Study of the Liver- Single Topic Conference on Autoimmune Liver Disease in Ottawa.

As you know our remit is autoimmune liver disease, and with my co-chair Dr. Aldo Montano-Loza, we hope you agree that the agenda is full and exciting!

Our goal is to encapsulate the science and practice of autoimmune liver disease in 2019, with a focus that spans from childhood into adulthood. The talks are by colleagues working nationally and internationally who have expertise in disease science, diagnosis and treatment.

Our intent is for discussion and engagement, and to bridge basic and clinical science. So once again we welcome you to Ottawa and look forward to the conference being a dynamic launch point for best clinical practice in autoimmune liver disease.

Gideon Hirschfield & Aldo Montano-Loza,

Scientific Co-Chairs

Presented by

Co-Developed by



Organizing Committee

Marc Bilodeau – CASL

Karen Seto – CLF

Scientific Co-Chairs

Gideon Hirschfield

Aldo Montano-Loza

Local Organizing Committee

Pascal Lapierre

Norma Choucha

Valérie-Ann Raymond



Event Manager

Liette Philippe

Schedule-at-a-glance

Friday, November 22nd

17:00-18:30	Onsite Registration	Main lobby of hotel
18:00-19:00	Welcome Reception	Celtic Foyer
19:00-22:30	Dinner & Keynote Dr Santamaria	Celtic Ballroom

Saturday, November 23rd

07:00-08:00	Breakfast and Onsite Registration	Celtic Foyer
08:00-12:30	Morning Sessions 1&2 Interactive Break Out Sessions	Celtic Ballroom 1. RTJ 2. Mulligan
12:30-13:30	Lunch	Celtic Foyer
13:30-17:30	Afternoon Sessions 3&4	Celtic Ballroom
19:00-19:30	Reception	Celtic Foyer
19:30-22:30	Dinner & Keynote Dr Vierling	Celtic Ballroom

Sunday, November 24th

07:00-08:00	Breakfast	Celtic Foyer
08:00-12:00	Morning Sessions 5 Interactive Break Out sessions	Celtic Ballroom 1. RTJ 2. Mulligan

Scientific Program

Friday, November 22

- 18:00** **Welcome reception**
- 19:00** **Dinner**
- 19:30** **Immunologic insights into liver disease: Nano-medicines as the future?**
Pere Santamaria, University of Calgary, Canada

Saturday, November 23

Session 1 – Disease presentation and clinical diagnosis

Chairs: Drs Gideon Hirschfield & Aldo Montano-Loza

- 08:00** **The current status of epidemiology of autoimmune liver disease.**
- 08:20** Q&A Session
Mark Swain, University of Calgary, Canada
- 08:30** **Genetic predisposition and autoimmune liver disease.**
- 08:50** Q&A Session
Aliya Gulamhusein, University of Toronto, Canada
- 09:00** **Interactive Break Out Sessions:**
- 1 RTJ- Complexities of diagnosing autoimmune liver disease- insights from serology, histology and imaging.**
Ashley Stueck, Dalhousie University, Canada
- 2. Mulligan- Paediatric perspectives on autoimmune liver disease: Reaching a secure diagnosis of paediatric autoimmune liver disease**
Amanda Ricciuto, University of Toronto, Canada
- 10:00** **Coffee break**

Session 2 – Mechanistic themes in AILD

Chairs: Drs John Vierling and Cynthia Levy

10:30 **How do environmental triggers drive autoimmune liver disease presentation?**

10:50 Q&A Session

Andrew Mason, University of Alberta, Canada

11:00 **The microbiome and autoimmune liver disease - A new frontier?**

11:20 Q&A Session

Jessica Allegretti, Brigham and Women's Hospital, USA

11:30 **Biliary autoimmunity and primary biliary cholangitis: the journey from the biliary epithelium to the patient in clinic.**

11:50 Q&A Session

David Jones OBE, Newcastle University, United Kingdom

12:00 **Is B cell depletion therapy the missing bullet for new AILD therapies?**

12:20 Q&A Session

Fernando Alvarez, Université de Montréal, Canada

12:30 **Lunch**

Session 3 – Treatment paradigms

Chairs: Drs David Jones and Fernando Alvarez

13:30 **PBC: from established to next generation therapy.**

13:50 Q&A Session

Cynthia Levy, University of Miami, USA

14:00 **AIH: where is the future of treatment headed and what do patients value?**

14:20 Q&A Session

John Vierling, Baylor College, USA

14:30 **Treatment of AILD in children: what are the distinctions and what are the unmet needs?**

14:50 Q&A Session

Nanda Kerkar, University of Rochester Medical Center, USA

15:00 **Symptoms and AILD: from burden to intervention.**

15:20 Q&A Session

Catherine Vincent, Université de Montréal, Canada

15:30 **Coffee break**

Session 4 – Clinical trials: approaches and challenges to new therapies

Chairs: Drs Mark Swain and Nanda Kerkar

16:00 **PBC: Lessons learnt from the journey of surrogates and drug discovery.**

16:20 Q&A Session

Bettina Hansen, University of Toronto, Canada

16:30 **PSC: A story of therapeutic obstacles but renewed optimism?**

16:50 Q&A Session

Gideon Hirschfield, University of Toronto, Canada

17:00 **Trials and childhood autoimmune liver disease: How to deliver new therapies?**

17:20 Q&A Session

Orlee Guttman, University of British Columbia, Canada

19:00 **Reception**

19:30 **Dinner**

20:00 **A personal and professional history of autoimmune hepatitis.**

John Vierling, Baylor College, USA

Session 5 – Looking beyond traditional disease boundaries

Chairs: Drs Gideon Hirschfield and Aldo Montano-Loza

08:00 **Adult overlap syndromes – a case to explore.**

08:20 Q&A Session

Waine Bai, University of Alberta Hospital, Canada

08:30 **Lessons for Hepatologists from IgG4 disease – a case-based discussion.**

08:50 Q&A Session

Fernanda Onofrio, Toronto Centre for Liver Disease, Canada

09:00 **Interactive Break Out Sessions:**

1-RTJ- Gender and autoimmune liver disease: pregnancy and bone health.

Angela Cheung, Mayo Clinic, USA

2-Mulligan- How to transition the paediatric patient to adult care.

Susan Gilmour, Stollery Children's Hospital, University of Alberta, Canada

10:00 **Coffee break**

10:30 **Single cell transcriptomics: what potential does it hold to understand
autoimmune liver disease?**

10:50 Q&A Session

Sonya MacParland, University of Toronto, Canada

11:00 **Is there a real burden from recurrent autoimmune liver disease post-liver
transplant?**


11:20 Q&A Session

Aldo Montano-Loza, University of Edmonton, Canada

- 11:30 **Cholangiocarcinoma and PSC: Can we see hope ahead through science and surgery?**
- 11:50 **Q&A Session**
Sumera Rizvi, Mayo Clinic, USA
- 12:00 **Meeting conclusion and closing.**



Thank you for attending CASL-STC 2019



Pere Santamaria

Professor, Department of Microbiology, Immunology & Infectious Diseases

University of Calgary, Canada

Dr. Pere Santamaria is Professor in the Department of Microbiology, Immunology and Infectious Diseases and Director of the Julia McFarlane Diabetes Research Centre at the Cumming School of Medicine at the University of Calgary. He has published over 170 articles, holds 82 issued patents in several countries, including the US, and the EU, and has 122 patents pending. He has given >200 lectures since 1992. He is Scientific Founder of Parvus Therapeutics Inc.

The focus of most of P.S.'s scientific work has been to try to understand the immunogenetics and immunopathogenesis of autoimmune disorders, with a particular focus on type 1 diabetes, to try to find targets for therapeutic intervention. Early efforts focused on the relationship between genetic susceptibility and resistance to autoimmunity and T-cell tolerance. This work led to the discovery of a new therapeutic platform for the treatment of chronic inflammatory disorders based on nanomedicine. This therapeutic approach triggers the formation of extensive antigen- and disease-specific networks of regulatory T and B-cells that efficiently suppress the progression of several different autoimmune disorders without compromising normal immunity. Current efforts focus on dissecting the mechanisms that sustain and regulate these regulatory cellular networks, the developmental origin(s) of their cellular components and the molecules that control cell-to-cell communication within the networks. Mice humanized with peripheral blood mononuclear cells from patients are used to select candidate nanomedicines for clinical development. The ultimate goal is to bring this technology to the clinic.

Notes



Mark Swain

Professor, Department of Medicine

University of Calgary, Canada

Dr. Mark Swain is Professor of Medicine and Head of the Division of Gastroenterology and Hepatology at the University of Calgary, Canada. He currently holds the Cal Wenzel Family Foundation Chair in Hepatology. Dr. Swain is a clinician-scientist with a basic science research interest focused on two main areas: (i) deciphering how inflammatory liver diseases cause symptoms such as fatigue, impaired cognition (“brain fog”) and altered mood (depression and anxiety), and (ii) delineating the role of the innate immune system in regulating hepatic inflammation . His clinical research interests are focused in the areas of fatty liver disease (NAFLD), autoimmune liver disease and viral hepatitis.

Notes



Aliya Gulamhusein

Assistant Professor, Clinician Investigator,
Department of Medicine
University of Toronto, Canada

Dr. Aliya Gulamhusein completed her medical degree at the University of Western Ontario. She trained in Internal Medicine and Gastroenterology at the University of Toronto and subsequently completed a clinical and research fellowship in Advanced Hepatology and liver transplantation at Mayo Clinic, Rochester. She went on to pursue a Masters degree in Public Health at the Bloomberg School of Public Health at John's Hopkins before being recruited back home as an Assistant Professor and Clinician Investigator in the Division of Gastroenterology at the University of Toronto. Within the Toronto Center for Liver Disease, she is co-lead of the Autoimmune Liver Disease Clinic, a dedicated program focused on optimizing care for patients with PBC, PSC, and autoimmune hepatitis and she is actively involved in international consortia studying these diseases. She is a recipient of the Young Investigator Award from PSC Partners Canada and as an investigator, her aims are to develop improved risk stratification tools in the hopes of moving towards a personalized approach to care for patients with these diseases.

Notes



Ashley Stueck

Assistant Professor, Department of Medicine

Dalhousie University, Canada

Dr. Ashley Stueck is an Assistant Professor at Dalhousie University, Halifax, Nova Scotia, Canada and an Anatomical Pathologist specializing in Hepatobiliary and Gastrointestinal Pathology. She received her MD from the University of Saskatchewan in 2010, and completed Anatomical Pathology residency, during which she was mentored by and performed research with Dr. Ian Wanless, and became a Fellow of the Royal College of Physicians of Canada in 2015. She then undertook the Liver Pathology Fellowship at The Mount Sinai Hospital in New York, under the tutelage of Drs Swan Thung, Isabel Fiel, and Stephen Ward. Dr. Stueck's research interests include progenitor cell-based regeneration of human liver and regression of cirrhosis, the changing field of medical liver biopsy in the era of HCV cure, and combined hepatocellular-cholangiocarcinoma. She is enthusiastic about teaching liver pathology to the next generation of pathologists, as well as increasing interaction between hepatologists and hepatobiliary pathologists. She is a member of CASL, AASLD, USCAP, CAP-ACP, the Hans Popper Hepatopathology Society, the Laennec Liver Pathology Society, and the International Liver Pathology Study Group ("ELVES").

Notes



Amanda Ricciuto

Paediatric Gastroenterologist, Clinician-Investigator
The Hospital of Sick Children, Toronto, Canada

Dr. Amanda Ricciuto completed her medical degree and General Paediatrics training in Montreal at McGill University. She then moved to Toronto to complete fellowship training in Paediatric Gastroenterology at SickKids, including advanced training in the management of paediatric inflammatory bowel disease (IBD). During that time, she obtained a PhD in Clinical Epidemiology and Health Care Research at the Institute of Health Policy, Management and Evaluation at the University of Toronto. Her PhD focused on IBD-associated liver disease, with an emphasis on primary sclerosing cholangitis (PSC).

Dr. Ricciuto's areas of specialty include paediatric inflammatory bowel disease and IBD-associated liver disease, particularly primary sclerosing cholangitis.

Dr. Ricciuto's research interests include paediatric IBD generally, as well as the complex inter-relationship between IBD and primary sclerosing cholangitis. Her work has served to better delineate the phenotype of PSC-associated IBD in children and to guide monitoring strategies in this population. From a methodologic standpoint, she has a strong interest and expertise in longitudinal data analysis.

Notes



Andrew Mason

Professor, Department of Medicine & Dentistry
University of Alberta, Canada

Dr. Mason is a Professor of Medicine and an Alberta Heritage Foundation for Medical Research Senior Scholar. He trained at the Liver Unit, Kings College Hospital, in London, England and then moved to Washington University, St. Louis as a Gastroenterology Fellow to train in molecular virology. At Ochsner Clinic Foundation, New Orleans he became the Medical Director of Liver Transplantation and an Assistant Professor in the Department of Medicine, Tulane University Medical Center. He relocated to the University of Alberta in 2002; he is currently the Director Research for the Division of Gastroenterology and Director of The Applied Genomics Centre. In the laboratory, he has identified a human betaretrovirus in patients with the autoimmune liver disease, Primary Biliary Cirrhosis (PBC). His laboratory studies are now focused on investigating the prevalence of the human betaretrovirus in patients with PBC. A causal association of virus and disease is being investigated using an in vitro model of PBC and a mouse model of disease, which is also being used to find novel combination antiviral therapies for patients with PBC. Dr. Mason is also principal investigator for an international, multi-center, double blind, randomized controlled trial using highly active anti-retroviral therapy to treat patients with PBC.

Notes



Jessica Allegretti

Instructor of Medicine, Harvard Medical School. Division of Gastroenterology.

Brigham and Women's Hospital, Boston

Dr. Jessica Allegretti is currently on faculty in the Division of Gastroenterology at Brigham and Women's Hospital. During the past three years of fellowship she have dedicated herself to in depth clinical training in inflammatory bowel disease (IBD), clostridium *difficile* infection (CDI) as well as clinical research. During her fellowship she completed a Master in Public Health from the Harvard School of Public health. She was able to gain important skills to be able to design and conduct multiple clinical studies in the areas of IBD and CDI. Her research goals are to investigate the intestinal microbiome, its function and consequences of its alteration. Her current clinic focus is on both recurrent *c. difficile* infections and inflammatory bowel disease. She received a clinical research grant from the American College of Gastroenterology for her project "Investigation of Dysbiosis and Bile Salt Composition Associated with *C. difficile* Infection". Her major contribution to her field during fellowship has been her founding of the fecal transplant program for recurrent clostridium *difficile* infections at Brigham and Women's Hospital. She have worked very closely with the infectious disease department and hospital infection control. Now, many years later she have performed hundreds of fecal transplants making our center one of the largest. Her research goals are to investigate the intestinal microbiome, its function and consequences of its alteration. They have conducted several pilot studies and clinical trials investigating the use of fecal transplants in other disease processes in order to better understand the functional capacity of the gut microbiome.

Notes



David Jones

Professor, Department of Liver Immunology


PI UK-PBC research consortium

Newcastle University, UK

Professor Jones is Professor of Liver Immunology at Newcastle University and PI for the UK-PBC Research Consortium. He leads the internationally renowned autoimmune liver disease clinical service in Newcastle, hosted by the Newcastle upon Tyne Hospitals Foundation Trust (NUTH). He has worked in the area of the autoimmune liver disease Primary Biliary Cholangitis (PBC) for over 25 years, starting as an MRC Clinical Research and Clinician Scientist Fellow. Working initially on the underpinning biology of the disease he has translated key mechanistic discoveries into new approaches to therapy. The UK-PBC MRC Stratified Medicine programme, which he led, has revolutionised thinking in the disease, defining the unmet need, developing the clinical tools needed to quantify risk and identifying the patient groups who need enhanced therapy in PBC. He has led the evaluation, approval and implementation programmes for the first stratified therapy in PBC (and indeed any rare liver disease), Obeticholic Acid, which is now available across the NHS. He was also the Coordinator for the RARE-LIVER European Reference Network (ERN) which was established to support the development of clinical delivery programmes for rare liver disease (PBC is a rare disease) across Europe.

In addition to his clinical and research work he has a long interest in training and is the NIHR Dean for Faculty Trainees. He has played a key role in the development of new integrated academic pathways which will play a key role in developing the next generation of researchers in the area of Stratified Medicine and its underpinning technologies. In June 2018 he was awarded an OBE for his services to Liver Medicine and Clinical Academic Training.

Notes



Fernando Alvarez

Chief, Department of Gastroenterology, Hepatology and Nutrition, CHU Sainte-Justine

Professor, Université de Montréal, Canada

Dr. Fernando Alvarez studied medicine at the University of Buenos Aires and his pediatric training at the Children's Hospital of Buenos Aires. His postgraduate training in pediatric hepatology was conducted at the Bicêtre Hospital in Paris, under the direction of Professor Daniel Alagille, and he completed a research training at the Department of Cell Biology at New York University under the direction of Professor David Sabatini.

Dr. Alvarez is currently Professor of Pediatrics in the Division of Gastroenterology, Hepatology and Nutrition at the CHU-Sainte Justine of the University of Montreal. His clinical research interests include pediatric liver disorders and liver transplantation.

His laboratory was dedicated to the study of autoimmune hepatitis. The main contributions of the laboratory were the identification of CYP2D6 and FTCD as self-antigens recognized by LKM1 and LC1 autoantibodies, respectively, found in sera from patients with type 2 autoimmune hepatitis. In recent years, they have produced several animal models for the study of the autoimmune hepatitis pathogenesis, and investigated new therapeutic strategies.

Notes



Cynthia Levy

Assistant Director, Schiff Center for Liver Diseases

University of Miami Health System, USA

Dr. Levy is a Professor of Medicine, board-certified in Gastroenterology (recertified in 2016) and Transplant Hepatology (certified in 2012). Dr. Levy is the Program Director for the Transplant Hepatology Fellowship program at the University of Miami and Associate Director of the Schiff Center for Liver Diseases.

Dr. Levy's clinical research program focuses on cholestatic and autoimmune liver diseases, with emphasis on clinical trial design and conduct. She is a member of the steering committee for the International Primary Sclerosing Cholangitis Study group (IPSCSG) and serves as the Chair for the TARGET-Primary Biliary Cholangitis (PBC) national registry. Dr. Levy currently serves as a member of the Practice Guidelines Committee for the American Association for the Study of Liver Diseases (AASLD) and is a steering committee member for the Cholestatic and Autoimmune Liver Diseases Special Interest Group in AASLD. She is a member of the writing group for the new AASLD Practice Guidance document for PBC and has published over 80 original articles, reviews and editorials, in addition to book chapters. Previously, Dr. Levy served as an Assistant Professor of Medicine with the Division of Gastroenterology, Hepatology and Nutrition at the University of Florida and the Malcolm Randall VAMC in Gainesville, FL.

Dr. Levy received her M.D. from Universidade Federal do Rio de Janeiro (UFRJ). She completed house staff training both at her home University and subsequently at University of Miami/Jackson Memorial Hospital, in Miami, FL. Dr. Levy completed her 3-year Gastroenterology Fellowship at Mayo Clinic in Rochester, Minnesota, and a 1-year Transplant Hepatology Fellowship at University of Florida, in Gainesville, FL.

Notes



John Vierling

Professor, Department of Medicine

Baylor College of Medicine, USA

Dr. John Vierling is a tenured Professor of Medicine and Surgery and Chief of Hepatology at the Baylor College of Medicine in Houston, Texas. He also serves as Director of Advanced Liver Therapies (a clinical research unit for adult liver diseases), Baylor Liver Health and Program Director of the Hepatology and Liver Transplantation Fellowship. He obtained his undergraduate degree in Biology with Great Distinction from Stanford University and received his M.D. degree from Stanford University School of Medicine. His clinical interests include autoimmune and alloimmune liver diseases, liver transplantation, acute liver failure, viral hepatitis, non-alcoholic fatty liver disease, Wilson disease and drug-induced liver injury (DILI). His translational research interest is immunologic mechanisms of hepatobiliary injury. He has authored over 250 manuscripts, reviews and chapters. His honors include Phi Beta Kappa, Alpha Omega Alpha, Best Doctors in America, Top 1% physician rating by U.S. News and World Report, Who's Who in America, Who's Who in the World, Who's Who in Science and Engineering and Who's Who in Healthcare. He serves on the NIH NIDDK Liver Tissue and Cell Distribution System Coordinating Committee and the DSMB for their DILI Network. He is a past president of the American Association for the Study of Liver Diseases, Secretary-Treasurer of Digestive Disease Week® and Chairman of the National Board of Directors of the American Liver Foundation.

Notes



Nanda Kerkar

Professor, Department of Pediatric

University of Rochester Medical Center, New York

Adjunct Professor, Department of Pediatric

University of southern California, Los Angeles

Dr. Nanda Kerkar, MD has trained at King's College Hospital, London, United Kingdom as a hepatologist/liver transplant physician and did her research in the laboratory on autoimmune liver disease at the Institute of Hepatology, University College London. Her research was focused on establishing an assay for the detection of liver kidney microsomal antibody type 1 (LKM1) and using the assay for epitope mapping studies on cytochrome P4502D6, the target of LKM1 in an effort to study the role of molecular mimicry in the pathogenesis of autoimmune hepatitis. She was also involved in the first description of 'de novo' autoimmune hepatitis, a form of graft dysfunction occurring in pediatric liver transplant recipients. She has been practicing in the United States since 2002 and was the Medical director of the Pediatric Liver Transplant Programs at Mount Sinai School of Medicine, New York and then Children's Hospital of Los Angeles, California before moving to Rochester, New York in 2017 to establish a Liver Transplant Program for children in Rochester. She is Professor of Pediatrics at University of Rochester Medical Center and Director of Pediatric Hepatology and Liver Transplantation at Golisano Childrens Hospital in Strong Memorial in Rochester. She is also Adjunct Professor of Pediatrics at University of Southern California on Los Angeles. She has been involved in highly productive clinical research in children's liver disease and has been named to the American Pediatric Society in 2014. She has lectured nationally and internationally and has over 100 peer reviewed publications.

Notes



Catherine Vincent

Head of the Hepatology and Liver Transplantation CHUM
Clinical Associate Professor, CHUM
Associate clinical scientist, CRCHUM

Université de Montréal, Canada

Dr. Catherine Vincent is hepatologist at CHUM – Centre hospitalier de l’Université de Montréal, a clinical associate professor at the Université de Montréal and an associate clinical scientist at the CRCHUM (Centre de recherche du CHUM). She is currently at the head of the hepatology and liver transplantation division at the CHUM.

Dr Vincent completed medical school, Internal medicine Residency and her Gastroenterology and hepatology fellowship at the University of Montreal. Her research and clinical interests include auto-immune liver disease, cholestatic liver disease as well as transition care for pediatric patients. She is involved in the Canadian Network for Autoimmune liver disease at the steering committee.

Notes



Bettina Hanson

Associate Professor, Department of Medicine
University of Toronto, Canada

Dr. Bettina E Hansen is Senior Biostatistician and Associate Professor at Toronto Centre for Liver Disease, Toronto General Hospital, at the University of Toronto. She Studied Mathematics and Statistics at the University of Copenhagen, Denmark and defended her PhD at the department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

Bettina supervises and lead a team of more than 15 PhD and MSc candidates in their clinical research of the liver. This involves conduction and management of huge international clinical trials, and follow-up studies as well as initiation of national registries and screening studies, but also smaller centre specific studies. In collaboration with national and international scientists, she has coordinated several large impact global studies on antiviral treatment for viral hepatitis: HBV 99-01, VIRID, PARC, ARES, PEGON, GIANT-B, PAS, PEGON, HCV Cohort Study, RETRACT and autoimmune liver disease: the Global PBC Group (PI) and the International PSC study group. For liver diseases in children she is involved in the initiation and conduction of two international registries of rare liver diseases; GALA, the biliary atresia network and NAPPED, the network for PFIC disease. In Canada she has initiated CaNAL the Canadian Network for Autoimmune Studies; focusing at present on PBC and AIH. She is active participating in the International HBV Forum and PSC Forum. Her aim is to conduct high quality research in the field of liver diseases. Her overall research objective is to make a valuable contribution to better identification of patients groups who will experience disease progression or may effectively respond to treatment.

Notes



Gideon Hirschfield

Professor, Department of Medicine
University of Toronto, Canada

Dr. Gideon Hirschfield is the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, at the Toronto Centre for Liver Disease. He is on faculty at the University of Toronto, and a Staff Physician at Toronto General Hospital. With broad expertise in advanced Hepatology, he is interested in particular, in understanding the pathophysiology and treatment of primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis.

Notes



Orlee Guttman

Fellowship Program Director

British Columbia Children's Hospital, Canada

Dr. Orlee Guttman pursued her fellowship in pediatric gastroenterology at the Hospital for Sick Children, and completed a Master's degree in Health Professional Education at the Ontario Institute for Studies in Education at the University of Toronto. She is presently a staff pediatric gastroenterologist at British Columbia Children's Hospital where she is the Fellowship Program Director.

Notes



Wayne Bai

Hepatology Fellow

University of Alberta Hospital, Canada

Dr. Wayne Bai is a gastroenterologist trained in New Zealand and his area of interest is in portal hypertension. He is excited to be the hepatology fellow at University of Alberta Hospital to advance his passion in numerous research projects in this area. He look forward to presenting some intriguing patients seen at the liver transplant unit at CASL.

Notes




Fernanda de Quadros Onofrio

Clinical Hepatology Fellow, Toronto Centre for Liver Disease

University Health Network, University of Toronto

Dr. Onofrio is a Physician graduated from the Federal University of Rio Grande do Sul - Porto Alegre - Brazil in 2009 and then completed residency programs in Internal Medicine and Gastroenterology (2010-2014). Elective trainee in Gastroenterology in Ludwigshafen - Germany (2014). Specialist in Digestive Endoscopy by the Brazilian Society of Digestive Endoscopy (2015). Master's Degree in Hepatology by the Post-graduate Program of Hepatology of the Federal University of Health Sciences of Porto Alegre (2016). PhD in Hepatology by the Post-graduate Program of Hepatology of the Federal University of Health Sciences of Porto Alegre (2018). Currently Clinical Hepatology Fellow at Toronto Centre for Liver Disease - University Health Network, University of Toronto (2018-2020).

Notes



Angela Cheung

Mayo Clinic, USA

Notes



Susan Gilmour

Professor in Pediatrics

Stollery Children's Hospital

University of Alberta

Dr. Gilmour recently completed her second term as Chair of the Department of Pediatrics. Dr. Gilmour was initially appointed academic Chair, as well as Edmonton Zone Clinical Department Chair for Child Health with Alberta Health Services, in July 2019.

Dr. Gilmour joined the Faculty of Medicine and Dentistry in 1997 after completing her MD at the University of Saskatchewan and post-graduate training at The Hospital of Sick Children, University of Toronto, including a research fellowship with the Sick Kids Research Institute. Since joining the faculty, Dr. Gilmour has contributed to advancing academic pediatrics through her leadership, not only as Chair but in liver and multi-visceral transplantation, a comprehensive redevelopment of the Division of Pediatric Gastroenterology/Nutrition and the development of a post-graduate training program.

Since 2009, Dr. Gilmour built on the excellence of the department to promote the University of Alberta and the Stollery Children's Hospital into a national and international leader in Child Health. Throughout all her administrative duties, Dr. Gilmour has continued with her academic interests in the functional outcomes in children post-liver transplant. Specifically researching the neurocognitive, educational outcomes and quality of life post-transplant. More recently, the outcomes focus has been on nutrition, sarcopenia and physical function. Her interest in transplant and leadership has led to North American involvement in SPLIT and nationally with the Canadian Liver Transplant Network and the Canadian Blood Services, liver transplant advisory board.

Notes



Sonya MacParland

Assistant Professor, Department of Laboratory Medicine and Pathobiology and Immunology

University of Toronto, Canada

Sonya MacParland, PhD, is a Basic Scientist and Immunologist in the Toronto General Hospital's Soham & Shaila Ajmera Family Transplant Centre and an Assistant Professor in the University of Toronto's Departments of Laboratory Medicine and Pathobiology and Immunology. Dr. MacParland's research program is focused on translating fundamental knowledge about the immune biology of the liver into clinical applications. Dr. MacParland and her research team are using advanced genomics including single cell RNA sequencing to describe the microenvironment of the healthy human liver. Her team recently developed the first transcriptomic map of the human liver (Nature Communications; 2018) as a platform to examine how immune dysregulation drives liver diseases, including autoimmune hepatitis. Her team is also examining how the liver immune environment can be therapeutically targeted and manipulated using nanoparticles to slow or reverse ongoing damage (Nature Materials; 2016, ACS Nano; 2017).

Notes



Aldo Montano-Loza

Associate Professor, Department of Medicine

University of Alberta, Canada

Dr. Montano-Loza obtained his undergraduate training at the “Universidad de Guadalajara”, in Mexico, where he graduated with an MD degree in 1998. Then, he completed his Internal Medicine residency and Gastroenterology & Endoscopy training at the “Instituto Nacional de Ciencias Medicas y Nutricion”, in 2005, and obtained a Master Degree in Medical Science at the “Universidad Autonoma de Mexico”. He went to obtain further training in Autoimmune Liver Diseases under the mentorship of Dr. Albert J. Czaja at the Mayo Clinic in Rochester Minnesota in 2008, and in 2009, he finished another Fellowship in Advanced Hepatology and Liver Transplantation at the University of Alberta. He obtained his PhD in Medical Science in 2013. He was the recipient of the International Travel Training Grant from the American College of Gastroenterology in 2006, the Clinical Research Awards from the American College of Gastroenterology in 2011 and 2018, the Canadian National Transplant Research Program Innovation Grant Award in 2018 and the Canadian Liver Foundation designated liver transplant research grant for 2019.

He has written over 130 original publications, largely in the areas of his major interest: autoimmune liver diseases and liver transplantation. He was elected president of the Canadian Liver Transplant Network in 2017. Since 2009, Dr. Montano-Loza has joined the department of Medicine as Assistant Professor at the University of Alberta, and he was promoted to Associate Professor in 2015.

Notes



Sumera Rizvi

Assistant Professor, Department of Medicine

Mayo Clinic of Medicine and Science, Rochester, MN

Dr. Sumera Rizvi is an Assistant Professor of Medicine at the Mayo Clinic College of Medicine and Science and a member of the faculty in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, MN. She underwent training in internal medicine at the University of Pittsburgh Medical Center, and subsequently completed Gastroenterology and Transplant Hepatology fellowships at the Mayo Clinic, Rochester, MN. Her academic focus is hepatobiliary neoplasia and cholestatic liver diseases. Her research efforts are centered on the immunobiology of cholangiocarcinoma and development of combination immune-directed therapies for the treatment of cholangiocarcinoma.

Notes



2019 marks the **50th Anniversary** of the **Canadian Liver Foundation**.

Over the last 50 years, we have made significant progress in finding ways to prevent, treat and cure liver disease. From humble beginnings of trying to better understand how the liver functions, every discovery over the past five decades has given us the opportunity to save more lives.

To help us continue ***bringing liver research to life*** please make a special “50 for 50” donation today in support of liver research and education.

Visit liver.ca/celebrate50

Save the date!



CANADIAN
LIVER
MEETING



CONGRÈS
CANADIEN
d'HÉPATOLOGIE

February 28 to
March 1, **2020**
Le Westin Montréal



<https://www.canadianlivermeeting.ca>

casl-stc-2019.ca